Last updated on May 2020

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Brief description of study

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Clinical Study Identifier: NCT03701334

Find a site near you

Start Over

Novartis Investigative Site

Kelowna, BC Canada
  Connect »